Abstract 1596P
Background
Palliative care has shown a positive economic impact in oncology. However, research on its financial viability in oncology, especially in developing countries, is lacking. This study estimates hospitalization costs for cancer patients in the southeast region of Brazil.
Methods
We used a retrospective analysis of electronic medical records for cancer patients treated at a Cancer Center in the southeast region of Brazil. Inclusion criteria were adult patients with any type of cancer who had died at a hospital setting between January 2022 and March 2023. Patients were divided into two groups: those who received outpatient palliative care (OPCT) and those who did not receive any OPCT. Based on the available clinical outcomes of the sample, data was collected on the hospital admission date, length of stay until death, and the type of accommodation until death [admission at intensive care unit (ICU) versus general ward]. To estimate the costs, we used real-world data from private hospitals in the southeast region, measuring the general amounts spent on daily hospitalization and ICU stays, and their respective lengths of stay, without reference to any specific patient or procedures. We performed univariate comparisons using Linear Regression.
Results
Out of the 72 patients with cancer, 29 were followed by the OPCT team, while 43 were not. The average cost of hospitalization for patients who did not receive the OPCT was found to be R$ 20,000.00 (€ 3,651.00; SD = 9.19) higher than those who received OPCT (p = 0.03). We observed that patients who were admitted to the ICU had hospitalization cost, on average, R$ 17,800.00 (€ 3,249.00; SD = 9.61) more than those who stayed in general ward (p = 0.06).
Conclusions
Our study highlights the economic benefits of providing OPCT in a developing country. Based on this analysis, OPCT can reduce healthcare costs by decreasing the length of hospital stay and preventing unnecessary ICU admissions. Our study suggest that policymakers and healthcare providers should prioritize the provision of OPCT in Brazil, and this type of support should be considered as an essential component of end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncoclinicas.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1605P - The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
Presenter: Sichao Wang
Session: Poster session 05
1606P - Sarcopenia, depression, and modes of feeding among cancer patients
Presenter: Muhammad Khokhar
Session: Poster session 05
1607P - Patient perceptions of the efficacy, safety, and quality of the evidence available on medicinal cannabis: A survey of Australian cancer patients - comparing users to non-users
Presenter: Joseph Taylor
Session: Poster session 05
1608P - Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Presenter: Omer Dizdar
Session: Poster session 05
1609P - A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Presenter: Eun Hee Jung
Session: Poster session 05
1610P - A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Presenter: Pablo Flores Paco
Session: Poster session 05
1611P - Family carers’ experiences with brain metastases: A longitudinal qualitative study
Presenter: Tonje Lundeby
Session: Poster session 05
1612P - Demonstrating the complexity of need and the effectiveness of integrated palliative care: An analysis of routinely collected patient centred outcome measures
Presenter: Joanne Hayes
Session: Poster session 05
1613P - The BreakThrough cancer malnutrition
Presenter: Stefano De Santis
Session: Poster session 05
1614P - Integrated palliative care for patients referred for Chimeric Antigen Receptor T-cell (CAR-T) therapy: A service evaluation
Presenter: Rebekah Williams
Session: Poster session 05